Platinum-based treatment for well- and poorly differentiated pancreatic neuroendocrine neoplasms Journal Article
| Authors: | Pulvirenti, A.; Raj, N.; Cingarlini, S.; Pea, A.; Tang, L. H.; Luchini, C.; Chou, J. F.; Grego, E.; Marinova, I.; Capanu, M.; Landoni, L.; Scarpa, A.; Allen, P. J.; Klimstra, D. S.; Reidy-Lagunes, D. L. |
| Article Title: | Platinum-based treatment for well- and poorly differentiated pancreatic neuroendocrine neoplasms |
| Abstract: | OBJECTIVES: Pancreatic neuroendocrine neoplasms include well-differentiated tumors (PanNETs) and poorly differentiated carcinomas (PanNECs). Previous reports suggested a role for platinum-based therapy largely in PanNEC. We sought to investigate the role of platinum-based therapy in pancreatic neuroendocrine neoplasms regardless of tumor grade and differentiation. METHODS: Patients with pancreatic neuroendocrine neoplasms treated with platinum-based therapy at Memorial Sloan Kettering (1994-2016) and Verona University Hospital (2008-2016) were retrospectively identified. Response to treatment by RECIST v1.1, overall survival, and progression-free survival were defined. Among patients with available tissue, DAXX, ATRX, Rb, and p53 expression was evaluated to support the histologic grade of differentiation. RESULTS: Fifty PanNETs, 29 PanNECs, and 22 high-grade tumors with undeterminable differentiation were included. No patients achieved complete response. Overall rate of partial response was 31%, 41% for PanNEC, and 20% for PanNETs. Among PanNETs, partial response was achieved in 33% of G1 (2/6), 10% of G2 (2/19), and 24% of G3 (6/25) tumors. Median overall survival was 29.3 months for PanNETs and 10.9 months for PanNEC (P < 0.001). There was no significant difference in median progression-free survival (P = 0.2). CONCLUSIONS: Platinum-based therapies demonstrated increased activity in PanNEC; however, promising efficacy was also observed in PanNETs, irrespective of grade. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. |
| Journal Title: | Pancreas |
| Volume: | 50 |
| Issue: | 2 |
| ISSN: | 0885-3177 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2021-02-01 |
| Start Page: | 138 |
| End Page: | 146 |
| Language: | English |
| DOI: | 10.1097/mpa.0000000000001740 |
| PUBMED: | 33565789 |
| PROVIDER: | scopus |
| PMCID: | PMC7880539 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 April 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work